The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress

Gastrointestinal Cancers MORE >>

Combining atezolizumab (Tecentriq) with bevacizumab (Avastin) induced promising and durable antitumor activity in patients with advanced hepatocellular carcinoma, according to findings from a phase Ib study presented during the 2018 ESMO Congress.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.